ストックスクリーナーアプリを入手
4.3851
0.09%
-0.0051
Nuvation Bio Inc (NUVB) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - Bluefield Daily Telegraph
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Investors to Reach Out | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment - MSN
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings - Yahoo Finance
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress - Insider Monkey
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings? - simplywall.st
5 Most Active Penny Stocks to Buy - Insider Monkey
Nuvation Bio Cancer Data Update Tests Valuation Gap After Share Pullback - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress - MSN
Nuvation Bio (NYSE:NUVB) Expands Cancer Story With Strong Update Nyse Composite Today - Kalkine Media
New Highs: Will Nuvation Bio Inc outperform the market in YEARWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Nuvation Bio set to present efficacy and safety results of ROS1 inhibitor at AACR26 - Traders Union
Lung cancer drug IBTROZI keeps responses going over 4 years in trial - Stock Titan
Nuvation Bio (NUVB) Is Down 6.1% After Eisai Deal And Stock Shelf Filing Has The Bull Case Changed? - simplywall.st
Nuvation Bio Inc. (NUVB) announces exclusive licensing agreement with Eisai to expand global reach of taletrectinib - MSN
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - marketscreener.com
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why - Insider Monkey
15 Best Penny Stocks to Buy According to Reddit - Insider Monkey
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss - simplywall.st
NUVB: IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications - TradingView
NUVB: Ibtrozi leads ROS1 market growth with superior efficacy and expanding first-line adoption - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPL - GlobeNewswire Inc.
Aug Setups: Will Nuvation Bio Inc outperform the market in YEARLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Nuvation Bio Earnings Call: IBTROZI Surge, Long Runway - The Globe and Mail
Nuvation Bio Faces Weak Start with 18.49% Gap Down Amid Market Concerns - Markets Mojo
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
Citigroup Inc. Has $3.42 Million Stake in Nuvation Bio Inc. $NUVB - MarketBeat
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
Nuvation Bio Stock Hits Day Low of $4.16 Amid Price Pressure - Markets Mojo
Nuvation Bio Hits Day High with Strong 8.72% Intraday Surge - Markets Mojo
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - The Globe and Mail
10 Best Low Cost Stocks to Buy Under $5 - Insider Monkey
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):